Furthermore, metformin treatment of two primary breast cancer cells MBCDF and MBCD17 downregulated mesenchymal signature genes vimentin and SNAIL and inactivated NFKB and STAT3 signaling pathways in response to IL-6 [41]. This evidence concerns the gene VIM and breast cancer.